Fast track — ArticlesEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Introduction
For more than three decades, postoperative radiotherapy has been standard treatment for newly diagnosed glioblastoma. Pooled analysis of six randomised trials of radiotherapy versus no radiotherapy after surgery showed significant survival benefits for radiotherapy.1, 2 However, the survival advantage after radiation was small and overall survival remained poor with almost no long-term survivors. The addition of nitrosourea-based chemotherapy gave modest further benefit: a meta-analysis of 12 randomised trials of adjuvant chemotherapy for high-grade glioma showed a 35% 1-year survival rate for glioblastoma, an improvement of 6%.3
In 2004, the European Organisation for Research and Treatment of Cancer (EORTC) 26981-22981/National Cancer Institute of Canada Clinical Trials Group (NCIC) CE3 randomised phase III trial showed the addition of concomitant and adjuvant temozolomide to standard postoperative radiotherapy improved median survival and 2-year survival relative to postoperative radiotherapy alone.4 Furthermore, patients whose tumour had a methylated promoter for the gene encoding O-6-methylguanine-DNA methyltransferase, MGMT, were more likely to benefit from the addition of temozolomide.5 Here we present long-term results on outcome and analyse known and putative prognostic and predictive factors. At the time of the initial analysis, whether the survival advantage would last over time was unclear.
Section snippets
Patients
Patients were recruited from daily practice in participating centres of the European Organisation for the Research and Treatment of Cancer (EORTC) and NCIC (webappendix). Eligible patients were aged 18–70 years with newly diagnosed and histologically proven glioblastoma (WHO grade IV astrocytoma), with a WHO performance status of 0–2 and adequate haematological, renal, and hepatic function. Patients on corticosteroid treatment had to receive a stable or decreasing dose for at least 14 days
Results
Between Aug 17, 2000, and March 22, 2002, 573 patients from 85 institutions in 15 countries were randomly assigned: 286 were assigned to receive initial radiotherapy alone, and 287 to receive concomitant and adjuvant temozolomide. Characteristics of patients in the two groups were well balanced (table 1). Details of treatment delivery, tolerance, and toxicity were published previously;4 figure 1 shows the trial profile.
For 485 (85%) of 573 patients, slides or tumour tissue was available for
Discussion
For many years, attempts to improve the dismal prognosis of patients with glioblastoma—including changes to radiotherapy schedules, doses, and techniques2, 12, 13 and the addition of nitrosourea-based chemotherapy combinations—have had little success.3 In the late 1990s, temozolomide14, 15 seemed promising for the treatment of recurrent anaplastic glioma; however, in glioblastoma, the objective response rates were only 5–8%.16, 17 A pilot phase II study18 showed that concomitant temozolomide
References (51)
- et al.
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
Radiother Oncol
(2002) - et al.
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review
Eur J Cancer
(2004) - et al.
Health-related quality of life in patients with glioblastoma: a randomised controlled trial
Lancet Oncol
(2005) - et al.
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
Cancer Treat Rev
(1997) - et al.
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Ann Oncol
(2001) - et al.
Survival of human glioma cells treated with various combination of temozolomide and X-rays
Int J Radiat Oncol Biol Phys
(2000) - et al.
Primary brain tumours in adults
Lancet
(2003) - et al.
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Lancet Oncol
(2008) - et al.
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
Lancet Oncol
(2006) How not to treat cancer
Lancet Oncol
(2008)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Cancer Cell
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
N Engl J Med
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials
Lancet
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
N Engl J Med
MGMT gene silencing and benefit from temozolomide in glioblastoma
N Engl J Med
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
Biometrics
On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial
Biometrics
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
J Clin Oncol
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study
Cancer
Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study
Radiother Oncol
Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933
J Clin Oncol
Phase I trial of temozolomide using an extended continuous oral schedule
Cancer Res
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
Br J Cancer
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
J Clin Oncol
A novel tool to analyse MRI recurrence patterns in glioblastoma
Neuro Oncol
Cited by (6173)
Expression of overall survival-EMT-immune cell infiltration genes predict the prognosis of glioma
2024, Non-coding RNA ResearchGlioma nanomedicine: Design, fabrication and theranostic application
2024, Coordination Chemistry ReviewsCombinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care
2024, International Journal of Radiation Oncology Biology PhysicsIdentification of MGMT promoter methylation as a specific lipid metabolism biomarker, reveals the feasibility of atorvastatin application in glioblastoma
2024, Metabolism: Clinical and ExperimentalIKBKE promotes the ZEB2-mediated EMT process by phosphorylating HMGA1a in glioblastoma
2024, Cellular Signalling